Defence Therapeutics Inc. News Releases

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.World ADC San Diego is a leading global forum dedicated to antibody-drug...

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.Sherry Aulin is a finance executive with more than...

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.Since assuming the role of President and Chief Executive...

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Tue, 08 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward. Dear...

Defence Therapeutics Provides Updates on Sharing Agreement

Fri, 04 Sep 2026 18:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 2026.On March 6, 2026, the Company completed a...

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

Mon, 31 Aug 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capability of the Accum® platform,...

Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs

Mon, 17 Aug 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and development capabilities as it...

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

Tue, 04 Aug 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026.As part of the leadership transition, Mr. Sébastien Plouffe, Founder...

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

Wed, 08 Jul 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development activities. Hamilton has...

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

Wed, 17 Jun 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California.Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, and...